Access cutting-edge chronic lymphocytic leukemia treatment through this clinical trial at a research site in Berkeley. Study-provided care at no cost to qualified participants.
Access chronic lymphocytic leukemia specialists in Berkeley at no cost
This study follows strict safety protocols and ethical guidelines
All study-related chronic lymphocytic leukemia treatment provided free
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior therapy. The primary hypotheses are that (1) nemtabrutinib is non-inferior to ibrutinib or acalabrutinib with respect to objective response rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 by blinded independent centra
Sponsor: Merck Sharp & Dohme LLC
Check if you qualify for this chronic lymphocytic leukemia clinical trial in Berkeley, CA
If you're searching for chronic lymphocytic leukemia treatment options in Berkeley, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Berkeley research site is actively enrolling participants for this clinical trial. You'll receive care from experienced chronic lymphocytic leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.